Payment overview · 2025
General Payments
$7,323.55
370 reported records · 39 companies
Healthcare provider profile · identity verified
Keith V Preis, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · CHERRY HILL, NJ · NPI 1750317301
Verified facts
What the public records show
CMS Open Payments records show Keith V Preis, M.D. received $7,323.55 in general payments during 2025 across 370 reported records.
ABBVIE INC. accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Horizant, Ingrezza, Nurtec Odt, Qulipta, Ubrelvy, Vumerity, Zeposia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Horizant by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vumerity by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Zeposia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 976 records involving 466 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Zeposia by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,729.96 | 23.6% | 105 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $773.21 | 10.6% | 33 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $651.76 | 8.9% | 34 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $605.88 | 8.3% | 33 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $588.89 | 8.0% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $304.32 | 4.2% | 12 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $283.19 | 3.9% | 16 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $282.83 | 3.9% | 15 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $247.63 | 3.4% | 20 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $189.92 | 2.6% | 14 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $156.11 | 2.1% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $127.68 | 1.7% | 6 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $123.48 | 1.7% | 6 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $117.07 | 1.6% | 7 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $104.11 | 1.4% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $101.56 | 1.4% | 5 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $83.07 | 1.1% | 5 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $72.54 | 1.0% | 4 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $72.12 | 1.0% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $71.84 | 1.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.18 | 0.9% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.01 | 0.8% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $52.53 | 0.7% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $51.64 | 0.7% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $50.74 | 0.7% | 3 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $49.39 | 0.7% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $48.72 | 0.7% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $42.91 | 0.6% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $34.26 | 0.5% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $21.10 | 0.3% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $20.55 | 0.3% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $18.53 | 0.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.93 | 0.2% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.87 | 0.2% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $16.79 | 0.2% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.48 | 0.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.47 | 0.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.33 | 0.2% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $14.95 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $7,151.37 | 366 |
| Education | $172.18 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $1,044.39 | 72 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $876.21 | 64 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $671.96 | 10 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $484.58 | 32 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $467.01 | 23 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $287.82 | 11 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $270.84 | 8 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $247.63 | 20 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $195.70 | 15 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $189.36 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $178.56 | 12 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $178.56 | 12 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $173.80 | 11 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $161.64 | 4 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $134.14 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $127.68 | 6 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $123.48 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $121.30 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $117.07 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $109.94 | 8 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $104.11 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $101.56 | 5 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $82.84 | 4 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $72.54 | 4 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $72.12 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $71.84 | 4 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $62.01 | 4 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $52.53 | 2 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $50.74 | 3 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $49.39 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $48.72 | 3 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $39.01 | 2 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $35.47 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $35.36 | 2 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $35.25 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $33.71 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $32.90 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.75 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $27.76 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $11.36 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $11.36 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 25 | exact normalized | Medicare Part D |
| HORIZANT horizant |
2025 | Horizant | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 27 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 976 supporting records · 466 recipient NPIs · example record 1184381876 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 179 | 35 |
| Pregabalin | Pregabalin | 147 | 47 |
| Donepezil Hcl | Donepezil Hcl | 117 | 31 |
| Topiramate | Topiramate | 105 | 25 |
| Memantine Hcl Er | Memantine Hcl | 101 | 23 |
| Memantine Hcl | Memantine Hcl | 90 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 23 |
| Sumatriptan Succinate | Sumatriptan Succinate | 69 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | suppressed |
| Baclofen | Baclofen | 65 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 12 |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 12 |
| Modafinil | Modafinil | 39 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 39 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 36 | 12 |
| Horizant | Gabapentin Enacarbil | 34 | suppressed |
| Alprazolam | Alprazolam | 33 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 27 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Botox | Onabotulinumtoxina | 25 | 11 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Diazepam | Diazepam | 22 | 13 |
| Neupro | Rotigotine | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 18 | suppressed |
| Armodafinil | Armodafinil | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Qulipta | Atogepant | 15 | suppressed |
| Lamotrigine Er | Lamotrigine | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Tecfidera | Dimethyl Fumarate | 13 | suppressed |
| Teriflunomide | Teriflunomide | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Vumerity | Diroximel Fumarate | 12 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 11 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,323.55 · 370 records | ABBVIE INC. | ACTHAR, AUSTEDO XR, Auvelity, BOTOX, Briviact, CAPLYTA, CREXONT, DAYBUE, ELYXYB - CELECOXIB, EMGALITY, General - DBS, Gocovri, HORIZANT, Hizentra, INBRIJA, INGREZZA, KEVEYIS, KISUNLA, LUMRYZ, Leqembi, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Rystiggo, SMARTVEST, Sunosi, TRUDHESA, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VRAYLAR, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAKIX, XYWAV, Xeomin, ZAVZPRET, ZEPOSIA, ZTLido, Zilbrysq | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error